The US Institute for Supply Management's manufacturing Prices Index rose to 77.9 in September from 71.1 in August, indicating more widespread raw-material cost increases among manufacturers. This rise adds to inflation concerns as the Federal Reserve recently raised interest rates and hinted at potential further hikes. Despite higher costs, manufacturing growth continued with indexes above 50, signaling expansion. Investors await the upcoming US jobs report on October 2 for further economic insights.
The U.S. Factory Price Index rise and Bitcoin's price test near $85,000 provide economic context for market watchers. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 02, 2026 05:02 WIB: out of 50 priced major cryptocurrencies, 26 rose and 23 fell today. Notable movers include AAVE at Rp3.062.567 with a 7.94% increase and a typical hold time of 105 days, DOT at Rp21.048 down 3.95% with a 121-day hold, and XTZ at Rp5.815 up 3.93% with a 100-day hold.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
